Question-and-Answer Session
Operator
Your first question comes from the line of Alan Carr with Needham. Please proceed.
Alan Carr - Needham & Company
Hi, good afternoon. Thanks for taking my question, and congratulations on a good quarter.
Jack Lief
Thank you.
Alan Carr - Needham & Company
A question on partnering. What sort of impact has the six-month safety data had on your discussion? Are there any changes in level of interest and do you have different partners involved now, or potential partners involved in discussions now?
Jack Lief
Well, we see our partners relatively regularly, potential partners I should say, relatively regularly at various conferences throughout the year. Obviously, they are aware of what is going on. At last month’s Investor Conferences I noted that there were a number of large pharma representatives there at my presentation. So we have not begun serious discussions thus far regarding lorcaserin with a partner. However, I do not think that there is any rush and I think that we have time. I think the value will increase as we move closer to NDA.
Alan Carr - Needham & Company
Do you think having 12-month data available is going to have a major impact on where these discussions head?
Jack Lief
Well, I think 12 months is obviously better than six months and we think that six months was indicative of the long-term safety of our compound. But 12 months certainly is going to be better. Safety is always a work in progress so more information is always better, and I think we will have better opportunities for partnering as the study continues.
Alan Carr - Needham & Company
Okay. I have a question on 125. When can we expect to see full data from that? The second part of that is what sort of factors are you considering in terms of whether or not to conduct this second -- possibly a second Phase 2 trial?
Jack Lief
Well, we hope to publish. Bill Shanahan, my Chief Medical Officer, is sitting hear next to me. Bill, any visibility on publication and possible publication dates or anything like that?
Bill Shanahan
Sure. Firstly, we would of course look to an appropriate scientific forum in which to present the data such as - the Sleep Society meetings that come up would be one possibility, and we would hope to publish sometime perhaps next year or thereafter.
Jack Lief
- To read the full transcript on Seeking Alpha, click here »
